Watch Ticker

MAIA Biotechnology, Inc.

Go to MAIA Biotechnology, Inc. Website

$1.52

-0.06 (-3.80%)

Live

Previous Close

$1.52

Day Range

$1.51 - $1.57

Previous Day Range

$1.54 - $1.6

Market Cap

$48.6 million USD

Day Vol.

160578

Previous Day Vol.

99836

Currency

USD

Primary Exchange

NYSE American, LLC

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorpor...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Vandana Singh - MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients - Benzinga

MAIA Biotechnology's lung cancer drug THIO, sequenced with Regeneron's cemiplimab, has shown promising long-term benefits in advanced non-small-cell-lung-cancer patients who failed previous treatments. The treatment has been well-tolerated with lower toxicity than standard-of-care, and some patients have continued the treatment for over 12 months, demonstrating safety, efficacy, and ongoing benefits.

Related tickers: MAIA, REGN.

Read Full Article

MAIA Biotechnology, Inc. - MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

Related tickers: MAIA.

Read Full Article

Trending Tickers

Please sign in to view